PDCD1 and esophageal squamous cell carcinoma: There is an increasing consensus that monoclonal antibody (mAb) inhibition of programmed death 1 (PD1) or programmed death ligand 1 (PD-L1) can yield convincing responses and clinical advantages across numerous malignancies, including ESCC (4, 5).